U.S. Markets closed

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 39% Share Price Gain

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll see some that fall short of the average. Unfortunately for shareholders, while the Harvard Bioscience, Inc. (NASDAQ:HBIO) share price is up 39% in the last three years, that falls short of the market return. Unfortunately, the share price has fallen 21% over twelve months.

See our latest analysis for Harvard Bioscience

Harvard Bioscience isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over the last three years Harvard Bioscience has grown its revenue at 4.1% annually. Considering the company is losing money, we think that rate of revenue growth is uninspiring. The market doesn't seem too pleased with the revenue growth rate, given the modest 12% annual share price gain over three years. It seems likely that we'll have to zoom in on the data more closely to understand if there is an opportunity here.

Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGM:HBIO Income Statement, April 3rd 2019

If you are thinking of buying or selling Harvard Bioscience stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Investors in Harvard Bioscience had a tough year, with a total loss of 21%, against a market gain of about 10%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 1.8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Before spending more time on Harvard Bioscience it might be wise to click here to see if insiders have been buying or selling shares.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.